BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37883026)

  • 1. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
    He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
    Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
    Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
    J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
    Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
    Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
    Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.
    Giustozzi M; Becattini C; Roila F; Agnelli G; Mandalà M
    Cancer Treat Rev; 2021 Nov; 100():102280. PubMed ID: 34438237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
    Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
    J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between NSCLC Cells, CD8
    Freitas-Dias C; Gonçalves F; Martins F; Lemos I; Gonçalves LG; Serpa J
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
    Lee YG; Kim I; Lee E; Bang SM; Kang CH; Kim YT; Kim HJ; Wu HG; Kim YW; Kim TM; Lee KW; Lee SH; Kim DW; Heo DS
    Thromb Haemost; 2014 Jun; 111(6):1112-20. PubMed ID: 24477503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
    Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
    Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
    Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
    Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
    [No Abstract]   [Full Text] [Related]  

  • 13. The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.
    Zhang J; Yang L; Tian H; Xu R; Liu D
    Eur J Oncol Nurs; 2024 Apr; 69():102527. PubMed ID: 38377652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
    Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
    Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
    Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
    Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
    Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D; Qin J
    BMC Cancer; 2024 Jan; 24(1):153. PubMed ID: 38291354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
    Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
    Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.
    Cai Y; Dong H; Li X; Liu Y; Hu B; Li H; Miao J; Chen Q
    Cancer Med; 2023 Jan; 12(2):1217-1227. PubMed ID: 35758614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.
    Dong H; Liang X; Gao Y; Cai Y; Li X; Miao J; Wang W; Hu B; Li H
    Thorac Cancer; 2022 May; 13(9):1258-1266. PubMed ID: 35315227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.